Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS)

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common subtype of mature post-thymic T-cell neoplasms.
• It is a diagnosis of exclusion with diverse biology, clinical presentation, and outcomes.
• Patients often present with advanced stage disease and have a poor prognosis.

Purpose of the Study:

• To review the latest diagnostic criteria for PTCL-NOS.
• To discuss current and emerging treatment strategies for PTCL-NOS.
• To highlight the unmet need for improved therapeutic options.

Main Methods:

• Review of current literature on PTCL-NOS diagnosis and treatment.
• Analysis of treatment outcomes including overall response rates (ORR), complete response rates (CRR), and progression-free survival (PFS).
• Discussion of diagnostic markers including histopathology, immunophenotype (CD5/CD7 loss), and T-cell receptor (TCR) gene rearrangement.

Main Results:

• PTCL-NOS diagnosis relies on histopathology, aberrant T-cell immunophenotype, and TCR gene rearrangement, as specific mutations are lacking.
• Frontline anthracycline-based chemotherapy yields ORR of 50-60% and CRR of 20-30%, with a 5-year OS of 20-30%.
• Autologous stem cell transplant (ASCT) may improve outcomes in select patients, while newer agents show response rates up to 33% in relapsed/refractory settings.

Conclusions:

• PTCL-NOS remains a challenging diagnosis with poor outcomes despite current therapies.
• There is a critical need for novel and more effective treatment strategies.
• Further research and clinical trials are essential to improve patient survival and quality of life.